Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-BCMA T cells in Refractory or Relapsed Multiple Myeloma
NCT03380039Phase 1Unknown
- Sponsor
- Xinhua Hospital
- Start
- Oct 2017
- Primary completion
- Jul 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zevorcabtagene autoleucel in multiple myeloma (MM), sponsored by Xinhua Hospital. Primary endpoint: Number of participants with CAR-BCMA T cell therapy-related adverse events at 24 weeks. Status: unknown.
02
Drugs
zevorcabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03380039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03380039.